Therapy for gastroesophageal reflux disease: More is not necessarily better

American Journal of Gastroenterology

Volumn 98, Issue 9, 2003, Pages 1913-1915

  Metz, David C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

DRUG EFFICACY; DRUG USE; EDITORIAL; FOOD REGURGITATION; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LOW DRUG DOSE; PRESCRIPTION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REMISSION; SYMPTOM; ZOLLINGER ELLISON SYNDROME;

EID: 0141794551     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07668.x     Document Type: Editorial

References (21)

1. The Gallup Organization. Survey on heartburn across America, 1998. Princeton, NJ: The Gallup Organization, 1998.
2. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997;112:1798-810.
3. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000;160:1803-9.
4. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-9.
5. Inadomi JM, McIntyre L, Bernard L. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): A prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003;98:1940-1944.
6. Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001;121:1095-100.
7. Fass R, Ofman JJ, Sampliner RE, et al. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther 2000;14:389-96.
8. Johnsson F, Weywadt L, Solhaug JH, et al. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998;33:15-20.
9. Metz DC, Bochenek WJ and the Pantoprazole US Study Group. Pantoprazole maintenance therapy prevents relapse of erosive esophagitis. Aliment Pharmacol Ther 2003;17:155-64.
10. Howden CW, Henning JM, Huang B, et al. Management of heartburn in a large, randomized, community-based study: Comparison of four therapeutic strategies. Am J Gastroenterol 2001;96:1704-10.
11. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol 2001;96:303-14.
12. Jones MP, Sloan SS, Rabine JC, et al. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol 2001;96:1711-7.
13. Bytzer P, Talley NJ. Dyspepsia. Ann Int Med 2001;134:815-22.
14. Mearin F, Balbao A, Zarate N, et al. Placebo in functional dyspepsia: Symptomatic, gastrointestinal motor, and gastric sensorial responses. Am J Gastroenterol 1999;94:116-25.
15. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety. Ann Intern Med 1994;121:161-7.
16. Metz DC, Strader DB, Orbuch M, et al. Use of omeprazole in Zollinger-Ellison syndrome: A prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993;7:597-610.
17. Klinkenberg-Knol EC, Jansen JB, Lamers CB, et al. Temporary cessation of long-term maintenance treatment with omeprazole in patients with H2-receptor-antagonist-resistant reflux oesophagitis. Effects on symptoms, endoscopy, serum gastrin, and gastric acid output. Scand J Gastroenterol 1990;25:1144-50.
18. Waldum HL, Amestad JS, Brenna E, et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996;39:649-53.
19. Metz DC, Pratha V, Martin P, et al. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol 2000;95:626-33.
20. Bieszk N, Kale-Pradhan PB. The efficacy of extended-interval dosing of omeprazole in keeping gastroesophageal reflux disease patients symptom free. Ann Pharmacother 1999;33:638-41.
21. Pisegna JR, Norton JA, Slimak GG, et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirements in Zollinger-Ellison syndrome. Gastroenterology 1992;102:767-78.